| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 27 | 2025 | 3273 | 1.510 |
Why?
|
| Neoadjuvant Therapy | 11 | 2025 | 478 | 0.800 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2025 | 1536 | 0.680 |
Why?
|
| Mastectomy | 5 | 2025 | 271 | 0.540 |
Why?
|
| Lymph Node Excision | 2 | 2025 | 238 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 2658 | 0.390 |
Why?
|
| Lymph Nodes | 3 | 2025 | 560 | 0.350 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 166 | 0.340 |
Why?
|
| Hyperparathyroidism | 3 | 2002 | 65 | 0.340 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 115 | 0.300 |
Why?
|
| Parathyroid Neoplasms | 2 | 2002 | 61 | 0.290 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 2081 | 0.280 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2025 | 88 | 0.270 |
Why?
|
| Adenoma | 2 | 2002 | 260 | 0.260 |
Why?
|
| Middle Aged | 28 | 2025 | 29388 | 0.240 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 29 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2025 | 525 | 0.240 |
Why?
|
| Female | 37 | 2025 | 51533 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 133 | 0.220 |
Why?
|
| Sentinel Lymph Node | 1 | 2025 | 23 | 0.220 |
Why?
|
| Social Isolation | 1 | 2025 | 73 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 20 | 0.210 |
Why?
|
| Adult | 24 | 2025 | 29496 | 0.200 |
Why?
|
| Prognosis | 9 | 2025 | 4115 | 0.200 |
Why?
|
| Time-to-Treatment | 1 | 2025 | 156 | 0.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 107 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2025 | 108 | 0.190 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 83 | 0.180 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2002 | 14 | 0.180 |
Why?
|
| Mammaplasty | 3 | 2013 | 125 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 212 | 0.180 |
Why?
|
| Aged | 19 | 2025 | 21737 | 0.180 |
Why?
|
| Stress, Psychological | 1 | 2025 | 383 | 0.170 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 87 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 541 | 0.170 |
Why?
|
| Reoperation | 5 | 2013 | 728 | 0.170 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 233 | 0.170 |
Why?
|
| Adenocarcinoma | 5 | 2003 | 1212 | 0.170 |
Why?
|
| Humans | 41 | 2025 | 97979 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 4029 | 0.160 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1750 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 214 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 77 | 0.150 |
Why?
|
| Body Weight | 1 | 2021 | 456 | 0.150 |
Why?
|
| Postoperative Complications | 4 | 2013 | 2680 | 0.140 |
Why?
|
| Survival Rate | 5 | 2025 | 2043 | 0.140 |
Why?
|
| Axilla | 3 | 2025 | 109 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 200 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 1967 | 0.140 |
Why?
|
| Gastrinoma | 1 | 1996 | 2 | 0.130 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1996 | 10 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 222 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2025 | 10964 | 0.120 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 40 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3607 | 0.120 |
Why?
|
| Radiotherapy | 3 | 2013 | 325 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 720 | 0.110 |
Why?
|
| Biopsy | 3 | 2018 | 1224 | 0.110 |
Why?
|
| Adaptive Clinical Trials as Topic | 2 | 2025 | 8 | 0.100 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 7398 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 8 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2001 | 844 | 0.100 |
Why?
|
| Time Factors | 6 | 2025 | 5561 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1098 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 552 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 748 | 0.090 |
Why?
|
| Esophageal Neoplasms | 4 | 2003 | 353 | 0.090 |
Why?
|
| Lymphokines | 3 | 2002 | 74 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 206 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 602 | 0.080 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 921 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2019 | 483 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 770 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 864 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2003 | 373 | 0.080 |
Why?
|
| Breast | 2 | 2023 | 315 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2003 | 478 | 0.080 |
Why?
|
| Mammography | 3 | 2021 | 504 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 551 | 0.060 |
Why?
|
| Endothelium, Vascular | 4 | 2002 | 440 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1028 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 3210 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 4808 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 583 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2006 | 176 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2002 | 1394 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 194 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 96 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2025 | 168 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 284 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2025 | 207 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 176 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 707 | 0.050 |
Why?
|
| Chicago | 2 | 2025 | 1517 | 0.050 |
Why?
|
| Radiation, Ionizing | 2 | 2000 | 123 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2025 | 429 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 272 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2025 | 902 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 323 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2003 | 46 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2003 | 830 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 666 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 92 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 313 | 0.040 |
Why?
|
| Adolescent | 4 | 2015 | 10096 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2374 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 25 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 160 | 0.040 |
Why?
|
| Coumarins | 1 | 2000 | 15 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 988 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1291 | 0.040 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 400 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 265 | 0.040 |
Why?
|
| Young Adult | 3 | 2022 | 7529 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 1105 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1125 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 423 | 0.040 |
Why?
|
| Male | 6 | 2016 | 47043 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 98 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 43 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 98 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 55 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2019 | 285 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 263 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1527 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 356 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 370 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1999 | 255 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1032 | 0.030 |
Why?
|
| Anorexia | 1 | 1997 | 26 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 793 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 863 | 0.030 |
Why?
|
| Mice | 8 | 2005 | 12702 | 0.030 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 375 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 1997 | 181 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 1416 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 63 | 0.030 |
Why?
|
| Urinary Catheters | 1 | 2016 | 7 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1254 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1995 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 520 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 282 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2051 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 800 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1122 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 194 | 0.030 |
Why?
|
| Neoplasms | 2 | 2000 | 3340 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 639 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 393 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 280 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1717 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 418 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 224 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 229 | 0.020 |
Why?
|
| Cytokines | 1 | 1997 | 889 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1133 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2000 | 3607 | 0.020 |
Why?
|
| Animals | 8 | 2005 | 28907 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 340 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 426 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 2855 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2000 | 45 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 54 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 25 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1990 | 49 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 59 | 0.020 |
Why?
|
| Inflammation | 1 | 1997 | 1122 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 307 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 179 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 975 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 239 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2555 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 401 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 994 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1946 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4396 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1567 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1944 | 0.010 |
Why?
|
| Escherichia coli | 2 | 2000 | 571 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 1011 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 102 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1752 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 370 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 317 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 557 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1009 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 384 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 311 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 142 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 6255 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 58 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 310 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2063 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 153 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 280 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 292 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 218 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2000 | 4 | 0.010 |
Why?
|
| Endostatins | 1 | 2000 | 6 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 76 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 47 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 193 | 0.010 |
Why?
|
| Pichia | 1 | 2000 | 33 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 201 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 89 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 101 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 200 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 582 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 41 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 1016 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 87 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 102 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 720 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1609 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 41 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 815 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 299 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 101 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1997 | 136 | 0.010 |
Why?
|
| Interleukins | 1 | 1997 | 135 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 246 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1815 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1997 | 167 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 313 | 0.010 |
Why?
|
| Melanoma | 1 | 1999 | 524 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1254 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 1476 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 512 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 803 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1990 | 31 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 3623 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 9688 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 2458 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1990 | 813 | 0.000 |
Why?
|